Phaseline

Companies › BioCryst Pharmaceuticals

BioCryst Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Berotralstat
Plasma kallikrein inhibitor
KLKB1Phase 3Hereditary AngioedemaFeb 2027
BCX17725–Phase 1Netherton SyndromeDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06539507BCX17725Phase 1Netherton SyndromeImmunologyDec 2026
NCT05453968BerotralstatPhase 3Hereditary AngioedemaImmunologyFeb 2027

From the company's SEC filings

Cash and short-term investments of $375m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

KLKB1 (1)

Companies with the same targets

Kyowa Kirin KalVista Pharmaceuticals ADARx Pharmaceuticals Pharvaris Netherlands DiaMedica Therapeutics

Companies built like this

Pharvaris Netherlands KalVista Pharmaceuticals Sagimet Biosciences Hangzhou Highlightll Pharmaceutical Prime Gene Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.